Levetiracetam

Phase 2Completed
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Absence Seizures

Conditions

Absence Seizures

Trial Timeline

May 1, 2000 → May 1, 2003

About Levetiracetam

Levetiracetam is a phase 2 stage product being developed by UCB for Absence Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00545012. Target conditions include Absence Seizures.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (20)

NCT IDPhaseStatus
NCT03340064Phase 3Completed
NCT01618877Phase 1Completed
NCT01407523Phase 2Completed
NCT01398956Phase 3Completed
NCT01292837Phase 3Completed
NCT01063764Phase 3Completed
NCT00505934Phase 2Completed
NCT00627133Phase 2Withdrawn
NCT00535392Phase 2Completed
NCT00376766Phase 3Terminated
NCT00361010Pre-clinicalCompleted
NCT01318408ApprovedCompleted
NCT00367432Phase 3Completed
NCT00291655Phase 3Completed
NCT00324454Phase 2Completed
NCT00319605Pre-clinicalCompleted
NCT00307450ApprovedCompleted
NCT00279617Phase 3Completed
NCT00325182ApprovedCompleted
NCT00252954ApprovedCompleted

Competing Products

9 competing products in Absence Seizures

See all competitors